• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Sonata Fibroid Treatment
    • About Uterine Fibroids
    • The Sonata® System
    • Visit SonataTreatment.com
  • In the News
    • Sonata In the News
    • Press Releases
  • Company
    • About Us
    • Management
    • Investors
    • Board of Directors
    • Awards
    • Compliance
    • Careers
  • Resources
    • Safety Information
    • Education Resource Center
    • Request for Medical or Scientific Information
  • Manuals
  • Contact Us

Press Releases

Sonata System Assists Facilities Impacted by the COVID-19 Pandemic in Restarting Elective Gynecologic Procedures

Jun 22, 2020

Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing Redwood City, CA – June 22, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that its Sonata® System […]

Gynesonics Announces Publications on Healthcare Economic Analyses Demonstrating Cost Savings

Jun 4, 2020

The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids announced the publication of healthcare […]

Gynesonics Receives FDA Clearance to Market Next Generation Sonata System 2.1

May 28, 2020

EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Sonata® […]

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

Nov 11, 2019

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. – November 11, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the Sonata® 2 System in the United […]

Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access

Nov 8, 2019

Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and […]

Gynesonics Announces Five-Year Patient Outcomes with the Sonata System Published in Journal of Gynecologic Surgery

Mar 5, 2019

VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes  In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal […]

Gynesonics Announces Publication of Final SONATA IDE Pivotal Trial Results in the Journal, Obstetrics And Gynecology

Jan 10, 2019

Robust Outcomes Support the Potential of the Sonata System as a  First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE […]

Gynesonics Announces $75 Million Equity Financing

Jan 3, 2019

Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by […]

Gynesonics Technology to be Featured in Presentations at 2018 AAGL Global Congress

Nov 12, 2018

Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 – Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its Sonata® System for transcervical treatment of uterine fibroids will be featured in […]

Gynesonics Receives FDA Clearance to Market Sonata® System

Aug 22, 2018

Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to […]

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2021 Gynesonics · All Rights Reserved · WS 05198 Rev. H

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Privacy Policy

More information about our Privacy Policy